Stephen Coutts

Stephen Coutts has over 43 years’ experience in the pharmaceutical/biotech industry employing both small molecule and biologic approaches to drug development, as well as extensive immunoassay experience in two diagnostic companies. Most recently, he consults for a company bringing a redox-active cancer adjuvant to market that also has applications in tropical parasitic diseases. Before that he was Vice President of R&D at Alere San Diego, which has since been sold to Quidel and Abbott. Prior to that, he was CEO of Biocept Laboratories, a company that analyzes genetic content in circulating tumor cells that are captured in a microfluidic device. Prior to that, Coutts spent one year as a Director of Pharmaceutical Development at Cypress Biosciences, which was preceded by his role as a Co-Founder of Triad Therapeutics where he was a member of its Board of Directors, as well as its President and COO, from 1998 to the end of 2004. Since PROMISS Dx has been founded, Dr. Coutts has been working closely with the team by providing support and advice on moving PROMISS technology to market.